July 2024
1. URABE F, Suzuki H, Iwatani K, Kimura T, et al
   Editorial Comment on "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
   Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15537.
   

   >> Share

   
   
2. KIKUCHI E, Hayakawa N
   Editorial Comment to "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
   Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15541.
   

   >> Share

   
   
3. HATTORI Y, Fujiwara T, Hagimoto H, Kokubun H, et al
   Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer.
   Int J Urol. 2024 Jul 3. doi: 10.1111/iju.15524.
   

   >> Share

   
   
4. YASUDA Y, Numao N, Fujiwara R, Takemura K, et al
   Surgical outcomes and predictive value for major complications of robot-assisted radical cystectomy of real-world data in a single institution in Japan.
   Int J Urol. 2024;31:724-729.
   

   >> Share

   
   
5. ASAKAWA K, Waratani M, Massey O, Holbrook T, et al
   Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.
   Int J Urol. 2024;31:730-738.
   

   >> Share

   
   June 2024
6. FU H, Hillman E, Talluri S, Liang L, et al
   Comparison of the perioperative outcomes of using the Firefly system with indocyanine green during robotic-assisted cystectomy with urinary diversion.
   Int J Urol. 2024;31:646-652.
   

   >> Share

   
   
7. HARA T, Matsushita Y, Harada K, Fujimoto N, et al
   Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.
   Int J Urol. 2024;31:696-698.
   

   >> Share

   
   
8. UEMURA K, Ito H, Jikuya R, Kondo T, et al
   Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
   Int J Urol. 2024;31:678-684.
   

   >> Share

   
   
9. NAKAGAWA R, Izumi K, Toriumi R, Aoyama S, et al
   Does radical cystectomy have a better prognosis than bladder conservative treatment in the real world?
   Int J Urol. 2024;31:628-636.
   

   >> Share

   
   May 2024
10. MITSUI Y, Okawa M, Hori S, Uetani M, et al
    Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
    Int J Urol. 2024 May 31. doi: 10.1111/iju.15509.
    

    >> Share

    
    
11. MIKI J, Fukuokaya W, Taoka R, Saito R, et al
    Oncological outcomes of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: A nationwide multi-institutional study.
    Int J Urol. 2024 May 31. doi: 10.1111/iju.15505.
    

    >> Share

    
    
12. HAYAKAWA N, Kikuchi E
    Editorial Comment on "Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification
    Int J Urol. 2024 May 16. doi: 10.1111/iju.15495.
    

    >> Share

    
    
13. MIYAKE M
    Editorial Comment from Dr Miyake to Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node
    Int J Urol. 2024 May 3. doi: 10.1111/iju.15487.
    

    >> Share

    
    
14. KAWAI T, Matsuyama H, Kobayashi K, Ikeda A, et al
    Photodynamic diagnosis-assisted transurethral resection of bladder tumor for high-risk non-muscle invasive bladder cancer improves intravesical recurrence-free survival (BRIGHT study).
    Int J Urol. 2024 May 2. doi: 10.1111/iju.15483.
    

    >> Share

    
    
15. KONDO T
    Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:560-561.
    

    >> Share

    
    
16. ISHIHARA H, Takagi T
    Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:559-560.
    

    >> Share

    
    
17. KITA Y, Otsuka H, Ito K, Hara T, et al
    Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:552-559.
    

    >> Share

    
    
18. TANAKA T, Yamasaki K, Nofuji S, Maehana T, et al
    Development and preliminary evaluation of a novel procedure for creation of an ileal conduit stoma aimed at preventing parastomal hernia.
    Int J Urol. 2024;31:512-518.
    

    >> Share

    
    April 2024
19. MIYAKE M, Nishimura N, Nakahama T, Nishimoto K, et al
    Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.
    Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15474.
    

    >> Share

    
    
20. SHIOTA M, Nagakawa S, Tsukahara S, Matsumoto T, et al
    Independent validation of genetic risk model to progression after intravesical bacillus Calmette-Guerin therapy for non-muscle invasive bladder cancer.
    Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15484.
    

    >> Share

    
    
21. SAKURA Y, Yamashita R, Notsu A, Usui K, et al
    Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification.
    Int J Urol. 2024 Apr 12. doi: 10.1111/iju.15465.
    

    >> Share

    
    
22. LUO HL
    Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:421.
    

    >> Share

    
    
23. TAOKA R, Sugimoto M
    Editorial Comment on Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:418-419.
    

    >> Share

    
    
24. HIYAMA Y
    Editorial comment to Lower bleeding volume contributes to decreasing surgical site infection in radical cystectomy: A propensity score-matched comparison of open versus robot-assisted radical cystectomy.
    Int J Urol. 2024;31:437.
    

    >> Share

    
    
25. URABE F
    Letter to the Editor Re: Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:420.
    

    >> Share

    
    
26. HAYAKAWA N, Kikuchi E
    Editorial comment to "The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study".
    Int J Urol. 2024;31:402-403.
    

    >> Share

    
    
27. SAZUKA T
    Editorial Comment on "The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study".
    Int J Urol. 2024;31:401-402.
    

    >> Share

    
    
28. TAGUCHI S
    Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
    Int J Urol. 2024;31:348.
    

    >> Share

    
    
29. SOWANTHIP D, Zennami K, Bejrananda T, Nukaya T, et al
    Older versus younger patients in robot-assisted radical cystectomy with intracorporeal ileal conduit comparing safety and clinical outcomes.
    Int J Urol. 2024;31:370-378.
    

    >> Share

    
    
30. KAMEI J, Endo K, Yamazaki M, Sugihara T, et al
    Lower bleeding volume contributes to decreasing surgical site infection in radical cystectomy: A propensity score-matched comparison of open versus robot-assisted radical cystectomy.
    Int J Urol. 2024;31:430-437.
    

    >> Share

    
    
31. SASAHARA T, Yanagisawa T, Sugaya S, Hisakane A, et al
    Prognostic factors for overall survival in clinical node-positive patients with upper tract urothelial carcinoma.
    Int J Urol. 2024;31:386-393.
    

    >> Share

    
    
32. YU TY, Wang HJ, Sung MT, Chuang YC, et al
    Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:410-418.
    

    >> Share

    
    
33. NAKANO J, Urabe F, Kiuchi Y, Takamizawa S, et al
    The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study.
    Int J Urol. 2024;31:394-401.
    

    >> Share

    
    
34. URABE F, Ito K, Kimura T
    Letter to the Editor Re: Balancing diagnostic advancements with cardiovascular considerations in 5-aminolevulinic acid use for bladder tumors.
    Int J Urol. 2024;31:452.
    

    >> Share

    
    March 2024
35. MORI K, Hatakeyama S, Enokida H, Miyake H, et al
    Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.
    Int J Urol. 2024;31:194-207.
    

    >> Share

    
    
36. ISHIKAWA Y, Tanaka H, Fujiwara M, Nakamura Y, et al
    Incidence and predictors of intraoperative hypotension during transurethral bladder tumor resection with oral 5-aminolevulinic acid.
    Int J Urol. 2024;31:238-244.
    

    >> Share

    
    
37. MATSUKAWA A, Morizane S, Shimizu R, Teraoka S, et al
    Chronic kidney disease and Charlson comorbidity index predict complications after robot-assisted radical cystectomy: A single-center study in Japan.
    Int J Urol. 2024;31:231-237.
    

    >> Share

    
    February 2024
38. KONDO T
    Editorial Comment to Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
    Int J Urol. 2024;31:133.
    

    >> Share

    
    
39. SUHARA Y, Urabe F, Yoshihara K, Kurawaki S, et al
    Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
    Int J Urol. 2024;31:125-132.
    

    >> Share

    
    January 2024
40. UKIMURA O
    Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.
    

    >> Share

    
    
41. TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
    Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
    

    >> Share

    
    
42. NAGAKAWA S, Shiota M, Takamatsu D, Tsukahara S, et al
    Clinical features and oncological outcomes of bladder cancer microsatellite instability.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15370.
    

    >> Share

    
    
43. NAKAMOTO T, Yoshida T
    Response to Comment: Future goals of upper tract urothelial carcinoma endoscopic management.
    Int J Urol. 2024;31:90.
    

    >> Share

    
    
44. MORI K, Yanagisawa T, Fukuokaya W, Iwatani K, et al
    Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
    Int J Urol. 2024;31:25-31.
    

    >> Share

    
    
45. KIKUCHI E, Ng CF, Kitamura H, Ku JH, et al
    Controversies in terminology associated with management of BCG-unresponsive NMIBC in Asia-Pacific.
    Int J Urol. 2024;31:32-38.
    

    >> Share

    
    
46. JUE JS, Alameddine M, Armenakas NA
    Future goals of upper tract urothelial carcinoma endoscopic management.
    Int J Urol. 2024;31:89.
    

    >> Share

    
    December 2023
47. GOTO Y
    Editorial Comment on Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
    Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15360.
    

    >> Share

    
    
48. ARAI S
    Editorial Comment on Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
    Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15361.
    

    >> Share

    
    
49. HASHIMOTO T
    Editorial Comment to Enfortumab vedotin versus platinum rechallenge in post-platinum post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Int J Urol. 2023;30:1186-1187.
    

    >> Share

    
    
50. TAGUCHI S, Kawai T, Ambe Y, Kishitani K, et al
    Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Int J Urol. 2023;30:1180-1186.
    

    >> Share

    
    
51. KATO M, Uchida J
    Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
    Int J Urol. 2023;30:1068-1077.
    

    >> Share

    
    November 2023
52. TOMIYAMA E, Fujita K, Hashimoto M, Uemura H, et al
    Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15338.
    

    >> Share

    
    
53. ROSAZZA M, Soria F, Gontero P
    Editorial comment-Risk stratification and management of nonmuscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15340.
    

    >> Share

    
    
54. NUNES FM, Apolonio JD, Mota-Pinto A, Leao R, et al
    Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
    Int J Urol. 2023 Nov 14. doi: 10.1111/iju.15335.
    

    >> Share

    
    
55. MORI K
    Editorial Comment from Dr. Mori to texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:1059.
    

    >> Share

    
    
56. CHEN W, Yokoyama M, Waseda Y, Kobayashi M, et al
    Surgical outcomes of robot-assisted radical cystectomy in octogenarian or older patients: A Japanese nationwide study.
    Int J Urol. 2023;30:1014-1019.
    

    >> Share

    
    
57. KANEKO H, Fujiwara M, Tanaka H, Kimura K, et al
    Texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:1056-1058.
    

    >> Share

    
    October 2023
58. KU JH, Lee LS, Lin TP, Kikuchi E, et al
    Risk stratification and management of non-muscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
    Int J Urol. 2023 Oct 6. doi: 10.1111/iju.15309.
    

    >> Share

    
    
59. SHIGETA K
    Editorial Comments to "Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort".
    Int J Urol. 2023;30:859.
    

    >> Share

    
    
60. TABATA H, Tanaka T, Shindo T, Hashimoto K, et al
    Urethrectomy via parapenile incision to complete robot-assisted radical cystectomy in a spine position for male patients.
    Int J Urol. 2023;30:936-938.
    

    >> Share

    
    
61. SOMIYA S, Kobori G, Ito K, Nakagawa H, et al
    Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort.
    Int J Urol. 2023;30:853-858.
    

    >> Share

    
    September 2023
62. KIKUCHI E, Hayakawa N
    Editorial Comment to "Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study".
    Int J Urol. 2023 Sep 27. doi: 10.1111/iju.15311.
    

    >> Share

    
    
63. FUKUSHIMA H
    Editorial Comment to Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Int J Urol. 2023 Sep 22. doi: 10.1111/iju.15308.
    

    >> Share

    
    
64. SZARVAS T
    Editorial Comment to Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
    Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15296.
    

    >> Share

    
    
65. SATO T, Sano T, Kawamura S, Ikeda Y, et al
    Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study.
    Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15294.
    

    >> Share

    
    
66. KIKUCHI E, Hayakawa N
    Editorial Comment to "The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion".
    Int J Urol. 2023;30:786-787.
    

    >> Share

    
    
67. HARA T, Furukawa J, Okamura Y, Bando Y, et al
    The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion.
    Int J Urol. 2023;30:779-786.
    

    >> Share

    
    
68. TOMISAKI I, Harada M, Sakano S, Terado M, et al
    Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
    Int J Urol. 2023;30:738-745.
    

    >> Share

    
    
69. ITO K, Kita Y, Kobayashi T
    Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Int J Urol. 2023;30:696-703.
    

    >> Share

    
    
70. GOTO Y
    Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Int J Urol. 2023;30:704.
    

    >> Share

    
    August 2023
71. GOTO Y
    Editorial Comment to Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15286.
    

    >> Share

    
    
72. NISHIMURA N, Miyake M, Nakahama T, Miyamoto T, et al
    Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15283.
    

    >> Share

    
    
73. LIANG HQ, Liao NK, Yang SB, Wei QJ, et al
    Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
    Int J Urol. 2023 Aug 21. doi: 10.1111/iju.15276.
    

    >> Share

    
    
74. GOTO Y
    Editorial Comment to Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:647-648.
    

    >> Share

    
    
75. YOSHIDA T, Ohe C, Nakamoto T, Kinoshita H, et al
    Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:634-647.
    

    >> Share

    
    
76. KONDO T
    Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:657.
    

    >> Share

    
    
77. SAZUKA T
    Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:658.
    

    >> Share

    
    
78. OKUYAMA Y, Hatakeyama S, Tabata R, Fujimori D, et al
    Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:649-657.
    

    >> Share

    
    July 2023
79. MIYAKE M, Nishimura N, Fujii T, Fujimoto K, et al
    Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Int J Urol. 2023 Jul 31. doi: 10.1111/iju.15263.
    

    >> Share

    
    
80. HAGIMOTO H, Kambe T, Mine Y, Kokubun H, et al
    Necessity of prophylactic drainage tube in retroperitoneal laparoscopic nephroureterectomy with open distal ureterectomy: A matched-pair analysis.
    Int J Urol. 2023;30:579-584.
    

    >> Share

    
    
81. ISHII N, Hatakeyama S, Miura H, Tanaka R, et al
    Trends in the age of hospitalized patients with urological cancers: A 17-year experience.
    Int J Urol. 2023;30:572-578.
    

    >> Share

    
    May 2023
82. LIU Z, Leow JJ, Yong DZP
    Editorial Comment to Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
    Int J Urol. 2023 May 10. doi: 10.1111/iju.15200.
    

    >> Share

    
    
83. CHOO ZW, Leow JJ, Vong E, Chia PL, et al
    Editorial Comment to Impact of the coronavirus disease-2019 pandemic on the number of patients undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospect
    Int J Urol. 2023;30:471-472.
    

    >> Share

    
    
84. TSURUTA K, Majima T, Nishikimi T, Kashima A, et al
    Impact of the coronavirus disease 2019 pandemic on the number of undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospective study.
    Int J Urol. 2023;30:464-471.
    

    >> Share

    
    April 2023
85. MASTROIANNI R, Torregiani G, Simone G
    Editorial Comment on Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
    Int J Urol. 2023;30:373-374.
    

    >> Share

    
    
86. TAFURI A, Panunzio A, Gozzo A, Ornaghi PI, et al
    Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
    Int J Urol. 2023;30:366-373.
    

    >> Share

    
    March 2023
87. MATSUMOTO K
    Editorial Comment on Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study.
    Int J Urol. 2023 Mar 16. doi: 10.1111/iju.15177.
    

    >> Share

    
    
88. MOEEN AM
    Editorial Comment on Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter-related bladder discomfort in TURBT: A randomized, double-blind, controlled trial.
    Int J Urol. 2023;30:270-271.
    

    >> Share

    
    
89. CHEN W, Yokoyama M, Kobayashi M, Fan B, et al
    Trends of radical cystectomy and comparisons of surgical outcomes among surgical approaches focusing on robot-assisted radical cystectomy: A Japanese nationwide database study.
    Int J Urol. 2023;30:258-263.
    

    >> Share

    
    
90. MIYAKE M, Oda Y, Nishimura N, Shimizu T, et al
    Chemotherapy with gemcitabine and cisplatin downregulates tumor expression level of nectin-4 in a syngeneic model of murine MBT2 urothelial cancer cell line and C3H mice.
    Int J Urol. 2023;30:328-330.
    

    >> Share

    
    
91. SINGH A, Kayina CA, Naik N, Ganesh V, et al
    Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter related bladder discomfort in transurethral resection of bladder tumors: A randomized, double blind, controlled trial.
    Int J Urol. 2023;30:264-270.
    

    >> Share

    
    February 2023
92. MIYAMOTO T, Miyake M, Nakahama T, Nishimura N, et al
    Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study.
    Int J Urol. 2023 Feb 14. doi: 10.1111/iju.15162.
    

    >> Share

    
    
93. YANG H, Zhang Z, Zhao K, Zhang Y, et al
    Initial experience with 161 extraperitoneal laparoscopic radical cystectomy procedures: Comparison with transabdominal laparoscopic radical cystectomy.
    Int J Urol. 2023;30:155-160.
    

    >> Share

    
    January 2023
94. NASELLI A, Pirola GM
    Editorial Comment to Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
    Int J Urol. 2023 Jan 18. doi: 10.1111/iju.15150.
    

    >> Share

    
    
95. KATAYAMA S, Pradere B, Grossman NC, Potretzke AM, et al
    Biological and prognostic implications of biopsy upgrading for high-grade upper tract urothelial carcinoma at nephroureterectomy.
    Int J Urol. 2023;30:63-69.
    

    >> Share

    
    December 2022
96. NAKAMURA Y, Fukushima H, Yoshitomi K, Soma T, et al
    Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
    Int J Urol. 2022 Dec 27. doi: 10.1111/iju.15136.
    

    >> Share

    
    
97. TAGUCHI S, Kawai T, Nakagawa T, Miyakawa J, et al
    Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020).
    Int J Urol. 2022;29:1462-1469.
    

    >> Share

    
    November 2022
98. NISHIKAWA R, Miyake M, Morizane S, Shimizu R, et al
    C-reactive protein as a prognostic predictor for non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guerin therapy: A Japan Urological Oncology Group study analysis.
    Int J Urol. 2022 Nov 30. doi: 10.1111/iju.15106.
    

    >> Share

    
    
99. YAMAMOTO A, Kawashima A, Uemura T, Yamamichi G, et al
    Anticancer maintenance chemotherapy prolonged prognosis of metastatic urothelial carcinoma patients: A single institute retrospective study using propensity score matching.
    Int J Urol. 2022;29:1294-1303.
    

    >> Share

    
    September 2022
100. LEOW JJ, Chen K, Yuen JSP
     Editorial Comment to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle invasive bladder cancer.
     Int J Urol. 2022 Sep 12. doi: 10.1111/iju.15037.
     

     >> Share

     
     July 2022
101. IDE H
     Editorial Comment from Dr Ide to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
     Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14988.
     

     >> Share

     
     
102. NASELLI A, Pirola GM
     Editorial Comment from Dr Naselli and Dr Pirola to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
     Int J Urol. 2022 Jul 20. doi: 10.1111/iju.15000.
     

     >> Share

     
     
103. TOCHIGI K, Nagayama J, Bando S, Ishiyama A, et al
     Relationship between the number of lymph nodes dissected and prognosis in muscle-invasive bladder cancer in the era of neoadjuvant chemotherapy.
     Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14974.
     

     >> Share

     
     
104. MURAKAMI Y, Matsumoto K, Miyake M, Amano N, et al
     Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer.
     Int J Urol. 2022 Jul 20. doi: 10.1111/iju.14976.
     

     >> Share

     
     
105. ISHIYAMA Y
     Editorial Comment to Impact of early postoperative creatinine increase on mid-term renal function after cystectomy.
     Int J Urol. 2022;29:724.
     

     >> Share

     
     
106. MASTROIANNI R, Simone G
     Editorial Comment to Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.
     Int J Urol. 2022;29:684.
     

     >> Share

     
     
107. SARI MOTLAGH R, Schuettfort VM, Mori K, Katayama S, et al
     Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.
     Int J Urol. 2022;29:676-683.
     

     >> Share

     
     
108. TOGASHI K, Hatakeyama S, Yoneyama T, Hamaya T, et al
     Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
     Int J Urol. 2022;29:733-739.
     

     >> Share

     
     
109. KITA Y, Ito K, Sano T, Hashimoto K, et al
     Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
     Int J Urol. 2022;29:647-655.
     

     >> Share

     
     June 2022
110. TANAKA T, Shindo T, Hashimoto K, Kobayashi K, et al
     Management of hydronephrosis after radical cystectomy and urinary diversion for bladder cancer: A single tertiary center experience.
     Int J Urol. 2022 Jun 30. doi: 10.1111/iju.14970.
     

     >> Share

     
     
111. ARAI T, Sazuka T, Sato H, Imamura Y, et al
     Efficacy of photodynamic diagnosis-assisted transurethral resection of bladder tumor for T1 bladder cancer: Novel second transurethral resection initiatives utilizing photodynamic diagnosis.
     Int J Urol. 2022 Jun 20. doi: 10.1111/iju.14962.
     

     >> Share

     
     
112. NOHARA T
     Editorial Comment to Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.
     Int J Urol. 2022 Jun 19. doi: 10.1111/iju.14967.
     

     >> Share

     
     
113. TAOKA R, Sugimoto M
     Editorial Comment from Dr Taoka and Dr Sugimoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
     Int J Urol. 2022 Jun 11. doi: 10.1111/iju.14954.
     

     >> Share

     
     
114. MATSUMOTO K
     Editorial Comment from Dr Matsumoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
     Int J Urol. 2022 Jun 9. doi: 10.1111/iju.14955.
     

     >> Share

     
     
115. SHINDO T, Maehana T, Tanaka T, Hashimoto K, et al
     Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.
     Int J Urol. 2022 Jun 2. doi: 10.1111/iju.14941.
     

     >> Share

     
     
116. ZENNAMI K, Sumitomo M, Hasegawa K, Kozako M, et al
     Risk factors for postoperative ileus after robot-assisted radical cystectomy with intracorporeal urinary diversion.
     Int J Urol. 2022;29:553-558.
     

     >> Share

     
     May 2022
117. LEE AY, Allen JC Jr, Teoh JY, Kang SH, et al
     Predicting perioperative outcomes of robot-assisted radical cystectomy: Data from the Asian Robot-Assisted Radical Cystectomy Consortium.
     Int J Urol. 2022 May 25. doi: 10.1111/iju.14937.
     

     >> Share

     
     
118. WANG Z, So WZ, Loh KY, Lim YK, et al
     Predictive biomarkers of response to bacillus Calmette-Guerin immunotherapy and bacillus Calmette-Guerin failure for non-muscle invasive bladder cancer.
     Int J Urol. 2022 May 22. doi: 10.1111/iju.14921.
     

     >> Share

     
     
119. MIYAKE M, Kikuchi E, Shinozaki K, Piao Y, et al
     Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
     Int J Urol. 2022 May 21. doi: 10.1111/iju.14933.
     

     >> Share

     
     
120. HIRATA Y, Higuchi M, Osawa T, Hinotsu S, et al
     Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.
     Int J Urol. 2022 May 21. doi: 10.1111/iju.14936.
     

     >> Share

     
     
121. FUJITA N, Hatakeyama S, Momota M, Narita T, et al
     Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guerin therapy.
     Int J Urol. 2022 May 16. doi: 10.1111/iju.14926.
     

     >> Share

     
     
122. KANNO T, Kobori G, Ito K, Nakagawa H, et al
     Complications and their management following retroperitoneal lymph node dissection in conjunction with retroperitoneal laparoscopic radical nephroureterectomy.
     Int J Urol. 2022;29:455-461.
     

     >> Share

     
     April 2022
123. TELLINI R, Mari A, Minervini A
     Editorial Comment from Dr Tellini et al. to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
     Int J Urol. 2022 Apr 5. doi: 10.1111/iju.14895.
     

     >> Share

     
     
124. HAYAKAWA N, Kikuchi E
     Editorial Comment from Dr Hayakawa and Dr Kikuchi to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
     Int J Urol. 2022 Apr 2. doi: 10.1111/iju.14888.
     

     >> Share

     
     
125. MIYAKE M
     Editorial Comment to Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma.
     Int J Urol. 2022;29:364-365.
     

     >> Share

     
     
126. OZAKI K, Hatakeyama S, Hamaya T, Okita K, et al
     Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma.
     Int J Urol. 2022;29:362-364.
     

     >> Share

     
     March 2022
127. NASELLI A, Pirola GM
     Editorial Comment from Dr Naselli and Dr Pirola to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
     Int J Urol. 2022 Mar 31. doi: 10.1111/iju.14883.
     

     >> Share

     
     
128. KOBAYASHI K, Matsuyama H, Kawai T, Ikeda A, et al
     Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
     Int J Urol. 2022 Mar 15. doi: 10.1111/iju.14854.
     

     >> Share

     
     
129. URABE F, Matsuzaki J, Ito K, Takamori H, et al
     Serum microRNA as liquid biopsy biomarker for the prediction of oncological outcomes in patients with bladder cancer.
     Int J Urol. 2022 Mar 14. doi: 10.1111/iju.14858.
     

     >> Share

     
     February 2022
130. IDE H
     Editorial Comment from Dr Ide to Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study.
     Int J Urol. 2022 Feb 25. doi: 10.1111/iju.14837.
     

     >> Share

     
     
131. KOGA F
     Editorial Comment to Predicting factor analysis of postoperative complications after robot-assisted radical cystectomy: Multicenter KORARC database study.
     Int J Urol. 2022 Feb 20. doi: 10.1111/iju.14832.
     

     >> Share

     
     
132. TAOKA R, Sugimoto M
     Editorial Comment to Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study.
     Int J Urol. 2022 Feb 15. doi: 10.1111/iju.14828.
     

     >> Share

     
     
133. LEOW JJ, Yong DZ, Chia PL
     Editorial Comment to Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium.
     Int J Urol. 2022 Feb 10. doi: 10.1111/iju.14818.
     

     >> Share

     
     
134. KIM H, Jeong BC, Lee S, Ku JH, et al
     Predicting factor analysis of postoperative complications after robot-assisted radical cystectomy: Multicenter KORARC database study.
     Int J Urol. 2022 Feb 8. doi: 10.1111/iju.14815.
     

     >> Share

     
     
135. YANG T, Liang H, Pei X, Zhang N, et al
     Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study.
     Int J Urol. 2022 Feb 5. doi: 10.1111/iju.14808.
     

     >> Share

     
     
136. IQBAL U, Houenstein HA, Elsayed AS, Jing Z, et al
     Ileal conduit versus neobladder: A propensity score-matched analysis of the effect on renal function.
     Int J Urol. 2022;29:158-163.
     

     >> Share

     
     
137. LIN MY, Niu SW, Li WM, Lee HL, et al
     Incidence and survival variations of upper tract urothelial cancer in Taiwan (2001-2010).
     Int J Urol. 2022;29:121-127.
     

     >> Share

     
     January 2022
138. SHINDO T
     Editorial Comment from Dr Shindo to Prognostication in Japanese patients with Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
     Int J Urol. 2022 Jan 4. doi: 10.1111/iju.14783.
     

     >> Share

     
     
139. GRAVESTOCK P, Coulthard N, Veeratterapillay R, Heer R, et al
     Response to Re: Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
     Int J Urol. 2022 Jan 1. doi: 10.1111/iju.14780.
     

     >> Share

     
     
140. CHEN CS, Li JR, Yang CK, Cheng CL, et al
     Significant predictors of contralateral upper tract recurrence after radical nephroureterectomy for upper tract urothelial carcinoma.
     Int J Urol. 2022;29:69-75.
     

     >> Share

     
     
141. KIJIMA T
     Editorial Comment to Programmed cell death-ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma.
     Int J Urol. 2022;29:91.
     

     >> Share

     
     
142. TOMIYAMA E, Fujita K, Hashimoto M, Miyamoto H, et al
     Programmed cell death-ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma.
     Int J Urol. 2022;29:89-90.
     

     >> Share

     
     December 2021
143. HAYAKAWA N, Kikuchi E
     Editorial Comment to Incidence and location of perioperative deep vein thrombosis in patients with bladder cancer undergoing radical cystectomy.
     Int J Urol. 2021 Dec 28. doi: 10.1111/iju.14777.
     

     >> Share

     
     
144. TAGUCHI S
     Editorial Comment from Dr Taguchi to Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis.
     Int J Urol. 2021 Dec 19. doi: 10.1111/iju.14768.
     

     >> Share

     
     
145. YUAN B, Cai L, Cao Q, Wu Q, et al
     Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis.
     Int J Urol. 2021 Dec 19. doi: 10.1111/iju.14748.
     

     >> Share

     
     
146. YOSHIDA S, Fujii Y
     Editorial Comment from Dr Yoshida and Dr Fujii to Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis.
     Int J Urol. 2021 Dec 19. doi: 10.1111/iju.14771.
     

     >> Share

     
     
147. GOPALAKRISHNAN D, Elsayed AS, Hussein AA, Jing Z, et al
     Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium.
     Int J Urol. 2021 Dec 19. doi: 10.1111/iju.14749.
     

     >> Share

     
     
148. SAZUKA T
     Editorial Comment to Prognostication in Japanese patients with Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
     Int J Urol. 2021 Dec 15. doi: 10.1111/iju.14770.
     

     >> Share

     
     
149. NISHIMURA N, Miyake M, Iida K, Miyamoto T, et al
     Prognostication in Japanese patients with Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
     Int J Urol. 2021 Dec 13. doi: 10.1111/iju.14759.
     

     >> Share

     
     
150. KIKUCHI H, Abe T, Matsumoto R, Osawa T, et al
     Outcomes of bacillus Calmette-Guerin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era.
     Int J Urol. 2021 Dec 11. doi: 10.1111/iju.14761.
     

     >> Share

     
     
151. YAMASHITA R, Nakamura M, Okayama Y, Kawase M, et al
     Incidence and location of perioperative deep vein thrombosis in patients with bladder cancer undergoing radical cystectomy.
     Int J Urol. 2021 Dec 9. doi: 10.1111/iju.14760.
     

     >> Share

     
     
152. GOMEZ-OSPINA JC, Garcia-Perdomo HA
     Re: Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
     Int J Urol. 2021 Dec 6. doi: 10.1111/iju.14764.
     

     >> Share

     
     
153. LONATI C, Moschini M
     Editorial Comment from Dr Lonati and Dr Moschini to Stage and cancer-specific mortality differ within specific Asian ethnic groups in upper tract urothelial carcinoma: North American population-based study.
     Int J Urol. 2021;28:1252-1253.
     

     >> Share

     
     
154. SHIOTA M
     Editorial Comment from Dr Shiota to Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study.
     Int J Urol. 2021;28:1253.
     

     >> Share

     
     
155. KATO M, Kobayashi T, Matsui Y, Ito K, et al
     Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.
     Int J Urol. 2021;28:1261-1267.
     

     >> Share

     
     
156. COLLA RUVOLO C, Wurnschimmel C, Nocera L, Wenzel M, et al
     Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study.
     Int J Urol. 2021;28:1247-1252.
     

     >> Share

     
     
157. SHIMIZU T, Hori S, Iemura Y, Tomioka A, et al
     Clinical significance of bladder deformity for intravesical recurrence after Bacillus Calmette-Guerin treatment.
     Int J Urol. 2021;28:1304-1305.
     

     >> Share

     
     November 2021
158. CHEN TJ, Chan TC, Li CF, Dilshan Sampath Dissanayaka D, et al
     High glycosyltransferase 8 domain containing two protein levels contribute to poor prognosis in urothelial carcinoma.
     Int J Urol. 2021;28:1178-1187.
     

     >> Share

     
     September 2021
159. POLIKARPOV DM, Campbell DH, Zaslavsky AB, Lund ME, et al
     Glypican-1 as a target for fluorescence molecular imaging of bladder cancer.
     Int J Urol. 2021 Sep 8. doi: 10.1111/iju.14683.
     

     >> Share

     
     
160. NASELLI A
     Editorial Comment to Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
     Int J Urol. 2021 Sep 7. doi: 10.1111/iju.14687.
     

     >> Share

     
     
161. HARADA M, Tomisaki I, Minato A, Onishi R, et al
     Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
     Int J Urol. 2021;28:970-974.
     

     >> Share

     
     
162. NARITA T, Hatakeyama S, Numakura K, Kobayashi M, et al
     Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
     Int J Urol. 2021;28:899-905.
     

     >> Share

     
     August 2021
163. GRAVESTOCK P, Coulthard N, Veeratterapillay R, Heer R, et al
     Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer.
     Int J Urol. 2021 Aug 27. doi: 10.1111/iju.14671.
     

     >> Share

     
     
164. SHINDO T, Hashimoto K, Tanaka T, Taguchi K, et al
     Therapeutic options to reduce intravesical recurrence in newly diagnosed Ta high-grade bladder cancer according to risk stratification: A multicenter retrospective study.
     Int J Urol. 2021 Aug 3. doi: 10.1111/iju.14657.
     

     >> Share

     
     
165. SETOGUCHI K, Saito K
     Editorial Comment from Dr Setoguchi and Dr Saito to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
     Int J Urol. 2021;28:821-822.
     

     >> Share

     
     
166. SHIGA M, Nagumo Y, Chihara I, Nitta S, et al
     Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
     Int J Urol. 2021;28:814-819.
     

     >> Share

     
     
167. HATAKEYAMA S, Ohyama C
     Editorial Comment from Dr Hatakeyama and Dr Ohyama to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
     Int J Urol. 2021;28:820.
     

     >> Share

     
     
168. SAZUKA T
     Editorial Comment from Dr Sazuka to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
     Int J Urol. 2021;28:820-821.
     

     >> Share

     
     July 2021
169. SHIN T, Mimata H
     "Early-pull-out" technique for intracorporeal ileal conduit urinary diversion after robot-assisted radical cystectomy.
     Int J Urol. 2021;28:778-779.
     

     >> Share

     
     May 2021
170. FAN J, Wu K, Zhang N, Yang T, et al
     Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial.
     Int J Urol. 2021 May 19. doi: 10.1111/iju.14592.
     

     >> Share

     
     
171. MIYATA Y, Matsuo T, Sakai H
     Editorial Comment to Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial.
     Int J Urol. 2021 May 19. doi: 10.1111/iju.14607.
     

     >> Share

     
     
172. KUROBE M
     Editorial Comment from Dr Kurobe to Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
     Int J Urol. 2021 May 3. doi: 10.1111/iju.14594.
     

     >> Share

     
     
173. IQBAL U, Durrani MM, Elsayed AS, Hussein AA, et al
     Functional outcomes after robot-assisted radical cystectomy: A review of literature.
     Int J Urol. 2021;28:493-501.
     

     >> Share

     
     
174. FARAJ KS, Rose KM, Navaratnam AK, Abdul-Muhsin HM, et al
     Effect of intracorporeal urinary diversion on the incidence of benign ureteroenteric stricture after cystectomy.
     Int J Urol. 2021;28:593-597.
     

     >> Share

     
     April 2021
175. LONATI C, Moschini M
     Editorial Comment from Dr Lonati and Dr Moschini to Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
     Int J Urol. 2021 Apr 22. doi: 10.1111/iju.14577.
     

     >> Share

     
     
176. URABE F
     Editorial Comment from Dr Urabe to Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
     Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14580.
     

     >> Share

     
     
177. SAITO R
     Editorial Comment from Dr Saito to Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
     Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14588.
     

     >> Share

     
     
178. KIJIMA T
     Editorial Comment from Dr Kijima to Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
     Int J Urol. 2021 Apr 21. doi: 10.1111/iju.14581.
     

     >> Share

     
     
179. HAYASHI Y, Fujita K, Banno E, Eich ML, et al
     Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
     Int J Urol. 2021 Apr 15. doi: 10.1111/iju.14574.
     

     >> Share

     
     
180. YAMASHITA S, Iguchi T, Koike H, Wakamiya T, et al
     Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer.
     Int J Urol. 2021 Apr 5. doi: 10.1111/iju.14569.
     

     >> Share

     
     March 2021
181. TEOH JY
     Editorial Comment to Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
     Int J Urol. 2021 Mar 28. doi: 10.1111/iju.14563.
     

     >> Share

     
     
182. HATANO K, Nonomura N
     Editorial Comment from Dr Hatano and Dr Nonomura to Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
     Int J Urol. 2021 Mar 28. doi: 10.1111/iju.14559.
     

     >> Share

     
     
183. SETOGUCHI K, Saito K
     Editorial Comment from Dr Setoguchi and Dr Saito to Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
     Int J Urol. 2021 Mar 27. doi: 10.1111/iju.14561.
     

     >> Share

     
     
184. FUKUSHIMA H
     Editorial Comment from Dr Fukushima to Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
     Int J Urol. 2021 Mar 26. doi: 10.1111/iju.14558.
     

     >> Share

     
     
185. TAOKA R, Tsunemori H, Matsuoka Y, Kohashiguchi K, et al
     Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
     Int J Urol. 2021 Mar 19. doi: 10.1111/iju.14548.
     

     >> Share

     
     
186. HAYAKAWA N, Kikuchi E
     Editorial Comment to Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched-pair analysis in a multicenter cohort.
     Int J Urol. 2021 Mar 18. doi: 10.1111/iju.14557.
     

     >> Share

     
     
187. MIYAMOTO T, Miyake M, Toyoshima Y, Fujii T, et al
     Clinical outcomes after intravesical bacillus Calmette-Guerin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019.
     Int J Urol. 2021 Mar 18. doi: 10.1111/iju.14545.
     

     >> Share

     
     
188. TULLY KH, Reese SW, Cole AP, Noldus J, et al
     Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
     Int J Urol. 2021 Mar 14. doi: 10.1111/iju.14550.
     

     >> Share

     
     
189. HUANG H, Yan B, Hao H, Shang M, et al
     Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
     Int J Urol. 2021 Mar 13. doi: 10.1111/iju.14537.
     

     >> Share

     
     
190. KANNO T
     Editorial Comment from Dr Kanno to Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
     Int J Urol. 2021 Mar 13. doi: 10.1111/iju.14551.
     

     >> Share

     
     
191. KUBOTA M, Kanno T, Inoue T, Yamasaki T, et al
     Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched-pair analysis in a multicenter cohort.
     Int J Urol. 2021 Mar 7. doi: 10.1111/iju.14533.
     

     >> Share

     
     February 2021
192. INOKUCHI J, Kuroiwa K, Nishiyama H, Kojima T, et al
     Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer.
     Int J Urol. 2021;28:208-214.
     

     >> Share

     
     November 2020
193. NAKAGAWA T
     Lymph node dissection for bladder cancer: Current standards and the latest evidence.
     Int J Urol. 2020 Nov 3. doi: 10.1111/iju.14398.
     

     >> Share

     
     
194. TANAKA H, Fujii Y
     Editorial Comment to Lymph node dissection for bladder cancer: Current standards and the latest evidence.
     Int J Urol. 2020 Nov 3. doi: 10.1111/iju.14419.
     

     >> Share

     
     
195. KOJIMA T
     Editorial Comment from Dr Kojima to Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma.
     Int J Urol. 2020;27:1031.
     

     >> Share

     
     
196. YOSHIDA T, Matsuda T
     Editorial Comment from Dr Yoshida and Dr Matsuda to Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma.
     Int J Urol. 2020;27:1030-1031.
     

     >> Share

     
     September 2020
197. TAOKA R, Matsuoka Y, Kohashiguchi K, Miura T, et al
     Impact of second transurethral resection on recurrence in patients with high-grade Ta bladder cancer.
     Int J Urol. 2020 Sep 28. doi: 10.1111/iju.14372.
     

     >> Share

     
     
198. KHETRAPAL P
     Editorial Comment to Benefits of robotic cystectomy compared with open cystectomy in an Enhanced Recovery After Surgery program: A propensity-matched analysis.
     Int J Urol. 2020;27:788-789.
     

     >> Share

     
     January 2020
199. HERR H
     Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette-Guerin?
     Int J Urol. 2020;27:72-74.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share